留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

对乙酰氨基酚和布洛芬治疗不同胎龄阶段早产儿动脉导管未闭的对照研究

郭利敏 马进 陈名武

郭利敏, 马进, 陈名武. 对乙酰氨基酚和布洛芬治疗不同胎龄阶段早产儿动脉导管未闭的对照研究[J]. 中华全科医学, 2021, 19(2): 248-251. doi: 10.16766/j.cnki.issn.1674-4152.001779
引用本文: 郭利敏, 马进, 陈名武. 对乙酰氨基酚和布洛芬治疗不同胎龄阶段早产儿动脉导管未闭的对照研究[J]. 中华全科医学, 2021, 19(2): 248-251. doi: 10.16766/j.cnki.issn.1674-4152.001779
GUO Li-min, MA Jin, CHEN Ming-wu. A comparative study of paracetamol and ibuprofen on patent ductus arteriosus in preterm infants at different stages of gestational age[J]. Chinese Journal of General Practice, 2021, 19(2): 248-251. doi: 10.16766/j.cnki.issn.1674-4152.001779
Citation: GUO Li-min, MA Jin, CHEN Ming-wu. A comparative study of paracetamol and ibuprofen on patent ductus arteriosus in preterm infants at different stages of gestational age[J]. Chinese Journal of General Practice, 2021, 19(2): 248-251. doi: 10.16766/j.cnki.issn.1674-4152.001779

对乙酰氨基酚和布洛芬治疗不同胎龄阶段早产儿动脉导管未闭的对照研究

doi: 10.16766/j.cnki.issn.1674-4152.001779
基金项目: 

安徽省自然科学基金 1608085MH196

详细信息
    通讯作者:

    马进, E-mail: majinlcyx@163.com

  • 中图分类号: R722.6

A comparative study of paracetamol and ibuprofen on patent ductus arteriosus in preterm infants at different stages of gestational age

  • 摘要:   目的  观察口服对乙酰氨基酚与布洛芬治疗不同胎龄早产儿动脉导管未闭(patent ductus arteriosus,PDA)的疗效和安全性。  方法  选取2016年1月—2018年1月在蚌埠医学院第三附属医院新生儿科住院的胎龄<37周,体重<2 500 g,口服布洛芬的56例PDA早产儿为对照组,2018年1月—2020年1月在蚌埠医学院第三附属医院新生儿科住院的胎龄<37周, 体重<2 500 g,54例PDA早产儿为观察组,予口服对乙酰氨基酚。所有患儿根据胎龄再分为3组,28~30+6周组,31~33+6周组,34~36+6周组;观察比较2种药物的疗效和安全性及3组不同胎龄早产儿PDA的关闭率差异。  结果  对乙酰氨基酚组动脉导管关闭率(79.63%)和布洛芬组(78.57%)比较差异无统计学意义(P>0.05)。28~30+6周组、31~33+6周组、34~36+6周组动脉导管关闭率分别为62.5%、84.2%、87.5%。对乙酰氨基酚组和布洛芬组之间上消化道出血、脑室内出血(intraventricular hemorrhage,IVH)、坏死性小肠结肠炎(necrotizing enterocolitis,NEC)、早产儿视网膜病(retinopathy of prematurity,ROP)、支气管肺发育不良(bronchopulmonary dysplasia,BPD)、尿量减少及高胆红素血症的发生率比较差异无统计学意义(均P>0.05)。  结论  对乙酰氨基酚与布洛芬均可有效治疗PDA;2种药物的不良反应发生率无显著差异;胎龄不同的早产儿动脉导管关闭率不完全相等,胎龄最小组关闭率最低。

     

  • 表  1  2组PDA早产儿一般资料比较

    组别 例数 性别(例) 胎龄(x±s,周) 出生体重(x±s,g)
    观察组 54 29 25 32.57±2.00 1 791.91±371.97
    对照组 56 26 30 32.47±2.03 1 782.21±390.19
    统计量 0.045a 0.254b 0.133b
    P 0.832 0.800 0.894
    注:a为χ2值,bt值。
    下载: 导出CSV

    表  2  不同治疗方法动脉导管未闭患儿不良反应发生率比较[例(%)]

    组别 例数 上消化道出血 NEC ROP BPD IVH 尿量减少 高胆红素血症
    观察组 54 5(9.26) 3(5.56) 3(5.56) 2(3.70) 2(3.70) 13(24.07) 16(29.63)
    对照组 56 3(5.36) 4(7.14) 2(3.57) 5(8.93) 1(1.79) 11(19.64) 13(23.21)
    χ2 0.316 0.583
    P 0.485a >0.999a 0.676a 0.438a 0.615a 0.574 0.445
    注:a为采用Fisher精确检验。
    下载: 导出CSV
  • [1] MEZU-NDUBUISI O J, AGARWAL G, RAGHAVAN A, et al. Patent ductus arteriosus in premature neonates[J]. Drugs, 2012, 72(7): 907-916. doi: 10.2165/11632870-000000000-00000
    [2] STOLLER J Z, DEMAURO S B, DAGLE J M, et al. Current perspectives on pathobiology of the ductus arteriosus[J]. J Clin Exp Cardiolog, 2012, 8(1): S8-001. http://www.omicsonline.org/2155-9880/pdfdownload.php?download=2155-9880-S8-001.pdf
    [3] GENTILE R, STEVENSON G, DOOLEY T, et al. Pulsed doppler echocardiographic determination of time of ductal closure in normal newborn infants[J]. J Pediatr, 1981, 98(3): 443-448. doi: 10.1016/S0022-3476(81)80719-6
    [4] SEMBEROVA J, SIRC J, MILETIN J, et al. Spontaneous closure of patent ductus arteriosus in infants ≤1 500 g[J]. Pediatrics, 2017, 140(2): e20164258. doi: 10.1542/peds.2016-4258
    [5] BENITZ W E. Patent ductus arteriosus in preterm infants[J]. Pediatrics, 2016, 137(1): 1-6.
    [6] OLGUN H, CEVIZ N, KARTAL I, et al. Repeated courses of oral ibuprofen in premature infants with patent ductus arteriosus: efficacy and safety[J]. Pediatr Neonatol, 2017, 58(1): 29-35. doi: 10.1016/j.pedneo.2015.04.017
    [7] ONCEL M Y, ERDEVE O. Safety of therapeutics used in management of patent ductus arteriosus in preterm infants[J]. Curr Drug Saf, 2015, 10(2): 106-112. doi: 10.2174/1574886309999141030142847
    [8] HÄRKIN P, HÄRMÄ A, AIKIO O, et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial[J]. J Pediatr, 2016, 177: 72-77. doi: 10.1016/j.jpeds.2016.04.066
    [9] CUZZOLIN L, BARDANZELLU F, FANOS V. The dark side of ibuprofen in the treatment of patent ductus arteriosus: could paracetamol be the solution?[J]. Expert Opin Drug Metab Toxicol, 2018, 14(8): 855-868. doi: 10.1080/17425255.2018.1492550
    [10] HAMMERMAN C, BIN-NUN A, MARKOVITCH E, et al. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment[J]. Pediatrics, 2011, 128(6): e1618-e1621. doi: 10.1542/peds.2011-0359
    [11] ONCEL M Y, YURTTUTAN S, ERDEVE O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial[J]. J Pediatr, 2014, 164(3): 510-514. doi: 10.1016/j.jpeds.2013.11.008
    [12] AL-LAWAMA M, ALAMMORI I, ABDELGHANI T, et al. Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus[J]. J Int Med Res, 2018, 46(2): 811-818. doi: 10.1177/0300060517722698
    [13] BAGHERI M M, NIKNAFS P, SABSEVARI F, et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus[J]. Iran J Pediatr, 2016, 26(4): e3975. http://www.onacademic.com/detail/journal_1000040554459710_77c9.html
    [14] HUANG X, WANG F, WANG K. Paracetamol versus ibuprofen for the treatment of patent ductus arteriosus in preterm neonates: a meta-analysis of randomized controlled trials[J]. J Matern Fetal Neonatal Med, 2018, 31(16): 2216-2222. doi: 10.1080/14767058.2017.1338263
    [15] OHLSSON A, SHAH P S. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants[J]. Cochrane Database Syst Rev, 2020, 1(1): CD010061. http://pdfs.semanticscholar.org/b214/b66f09949060fa95dca663f5566a8977c21e.pdf
    [16] 王乐, 赵婷, 李明霞. 早产儿动脉导管未闭高危因素及并发症分析[J]. 中国新生儿科杂志, 2015, 30(4): 273-276. https://cdmd.cnki.com.cn/Article/CDMD-10760-1014431911.htm
    [17] 高瑛, 孙岩, 王席娟, 等. 极低出生体质量儿动脉导管未闭及动脉导管再次开放的高危因素分析[J]. 新乡医学院学报, 2017, 34(7): 574-578. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX201707006.htm
    [18] 陈超, 张兰, 李登峰, 等. 动脉导管内径对早产儿有血流动力学改变的动脉导管未闭并发症影响分析[J]. 中华全科医学, 2020, 18(2): 191-193, 223. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202002008.htm
    [19] MADELENEAU D, AUBELLE M S, PIERRON C, et al. Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight[J]. PLoS One, 2015, 10(4): e0124804. doi: 10.1371/journal.pone.0124804
    [20] 杨波, 陈洋, 高翔羽, 等. 影响早产儿症状性动脉导管未闭发生及药物干预效果的相关因素分析[J]. 中华心脏与心律电子杂志, 2015, 3(1): 28-34.
    [21] EL-MASHAD A E, EL-MAHDY H, EL AMROUSY D, et al. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates[J]. Eur J Pediatr, 2017, 176(2): 233-240. doi: 10.1007/s00431-016-2830-7
    [22] OHLSSON A, WALIA R, SHAH S S. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants[J]. Cochrane Database Syst Rev, 2020, 2(2): CD003481. http://pdfs.semanticscholar.org/83e7/3f0de5007b2e946538a7d58f96116c554e9c.pdf
    [23] ONCEL M Y, ERAS Z, URAS N, et al. Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus[J]. Am J Perinatol, 2017, 34(12): 1185-1189. doi: 10.1055/s-0037-1601564
    [24] EL-FARRASH R A, EL SHIMY M S, EL-SAKKA A S, et al. Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial[J]. J Matern Fetal Neonatal Med, 2019, 32(21): 3647-3654. doi: 10.1080/14767058.2018.1470235
    [25] KARABULUT B, PAYTONCU S. Efficacy and safety of oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants[J]. Paediatr Drugs, 2019, 21(2): 113-121. doi: 10.1007/s40272-019-00331-z
  • 加载中
表(2)
计量
  • 文章访问数:  172
  • HTML全文浏览量:  108
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-05-15
  • 网络出版日期:  2022-02-19

目录

    /

    返回文章
    返回